Last reviewed · How we verify
AGN-210669 ophthalmic solution, 0.025% — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AGN-210669 ophthalmic solution, 0.025% (AGN-210669 ophthalmic solution, 0.025%) — Allergan.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AGN-210669 ophthalmic solution, 0.025% TARGET | AGN-210669 ophthalmic solution, 0.025% | Allergan | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AGN-210669 ophthalmic solution, 0.025% CI watch — RSS
- AGN-210669 ophthalmic solution, 0.025% CI watch — Atom
- AGN-210669 ophthalmic solution, 0.025% CI watch — JSON
- AGN-210669 ophthalmic solution, 0.025% alone — RSS
Cite this brief
Drug Landscape (2026). AGN-210669 ophthalmic solution, 0.025% — Competitive Intelligence Brief. https://druglandscape.com/ci/agn-210669-ophthalmic-solution-0-025. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab